THERAPIES FOR CANCER USING ISOTOPICALLY SUBSTITUTED LYSINE
申请人:Shchepinov Mikhail S.
公开号:US20110082208A1
公开(公告)日:2011-04-07
Methods of treatment and substances for treatment of cancer may use or cause the creation of isotopically modified lysine at levels that do not occur naturally.
Therapies for cancer using isotopically substituted lysine
申请人:Shchepinov Mikhail S.
公开号:US10029956B2
公开(公告)日:2018-07-24
Methods of treatment and substances for treatment of cancer may use or cause the creation of isotopically modified lysine at levels that do not occur naturally.
Control of lysyl oxidase activity through site-specific deuteration of lysine
作者:Nikolay B. Pestov、Irina A. Okkelman、Vadim V. Shmanai、Alaksiej L. Hurski、Amato J. Giaccia、Mikhail S. Shchepinov
DOI:10.1016/j.bmcl.2010.11.018
日期:2011.1
Lysyl oxidase (LOX) is implicated in several extracellular matrix related disorders, including fibrosis and cancer. Methods of inhibition of LOX in vivo include antibodies, copper sequestration and toxic small molecules such as beta-aminopropionitrile. Here, we propose a novel approach to modulation of LOX activity based on the kinetic isotope effect (KIE). We show that 6,6-D-2-lysine is oxidised by LOX at substantially lower rate, with apparent deuterium effect on V-max/K-m as high as 4.35 +/- 0.22. Lys is an essential nutrient, so dietary ingestion of D(2)Lys and its incorporation via normal Lys turnover suggests new approaches to mitigating LOX-associated pathologies. (C) 2010 Elsevier Ltd. All rights reserved.